Amgen data on drug with ‘undruggable’ target at ASCO gets muted reception

The company announced poster presentations for the ASCO virtual meeting on AMG 510, its KRAS G12c inhibitor, in patients with colorectal cancer and a broad range of cancers. But an analyst called the drug “unimpressive” outside of non-small cell lung cancer.

Leave a Reply